Cellectis S A : and Sanofi partner on alemtuzumab as lymphodepletion agent for allogeneic CAR-T

May 11, 2021 - Paris - Cellectis S.A. (NASDAQ: CLLS - Euronext Growth: ALCLS), a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-class products based on gene-edited allogeneic CAR T-cells ('UCART') in the field of immuno-oncology, and Sanofi (Euronext: SAN - NYSE: SNY), today entered into a partnership agreement and a supply agreement regarding alemtuzumab, an anti-CD52 monoclonal antibody, to be used as part of a lymphodepleting regimen in certain Cellectis sponsored UCART clinical trials.